ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-OR02

AKI, Glomerulonephritis, and Tubulointerstitial Nephritis Following Vaccination: VigiBase Analysis

Session Information

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology, Risk Factors, and Prevention

Authors

  • Yoon, Soo-Young, Kyung Hee University Hospital, Dongdaemun-gu, Seoul, Korea (the Republic of)
  • Lee, Hyo Jin, Kyung Hee University Hospital, Dongdaemun-gu, Seoul, Korea (the Republic of)
  • Kim, Dae Kyu, Kyung Hee University Hospital, Dongdaemun-gu, Seoul, Korea (the Republic of)
  • Kim, Jin sug, Kyung Hee University Hospital, Dongdaemun-gu, Seoul, Korea (the Republic of)
  • Kim, Yang Gyun, Kyung Hee University Hospital at Gangdong, Gangdong-gu, Seoul, Korea (the Republic of)
  • Moon, Ju young, Kyung Hee University Hospital at Gangdong, Gangdong-gu, Seoul, Korea (the Republic of)
  • Jeong, Kyunghwan, Kyung Hee University Hospital, Dongdaemun-gu, Seoul, Korea (the Republic of)
  • Hwang, Hyeon Seok, Kyung Hee University Hospital, Dongdaemun-gu, Seoul, Korea (the Republic of)
Background

Vaccination is the long-term established measure for disease prevention and worldwide outbreak of COVID-19 necessitates mass scale vaccination. However, there is a public concern on the risk of renal adverse reactions from several types of vaccination.

Methods

We analyzed VigiBase (n = 120,715,116 reports), the World Health Organization pharmacovigilance database from Dec 1967 to Jul 2022 using disproportionate Bayesian reporting. Information component (IC) compares observed and expected values to find the associations of vaccines with acute kidney injury (AKI), glomerulonephritis (GN) and tubulointerstitial nephritis (TIN).

Results

We found 5,484 AKI (13.8% fatal), 2,846 GN (29.4% fatal) and 289 TIN reports (23.2% fatal) as vaccine-associated adverse reactions. Almost reports indicated single drug suspected cases. Cumulative number of reports on AKI, GN and TIN gradually increased and Americas was most prevalent regions of reporting. Examining the different vaccines separately, reporting count of COVID-19 mRNA vaccines sharply increased and it solely was associated with significantly higher reporting of AKI (IC025 1.09) and TIN (IC025 0.48). Patients aged 12-17 years had the highest IC values for COVID-19 mRNA vaccine-associated AKI and TIN. Hepatitis B, encephalitis and COVID-19 mRNA vaccine were prominently over-reported among ten types of vaccines with significant signals of GN.

Conclusion

AKI, GN and TIN substantially occurred following vaccination and it was most noticeable in patients exposed to COVID-19 mRNA vaccines. Clinicians should consider the increased risk of renal adverse reactions after vaccination.